Adapting Drug Approval Pathways for Bacteriophage-Based Therapeutics

Area of Science:

• Microbiology
• Drug Development
• Regulatory Science

Background:

• The rise of multi-drug resistant bacteria necessitates novel antibacterial strategies.
• Bacteriophage therapy, using viruses that infect bacteria, has a history in Eastern Europe and growing recent evidence of efficacy.
• No whole phage or phage-derived products are currently approved for human therapeutic use in the EU or USA.

Purpose of the Study:

• To review the challenges and pitfalls in the current regulatory approval process for whole phage and phage-derived products.
• To explore alternative regulatory pathways that could facilitate the clinical adoption of phage therapy.

Main Methods:

• Review of existing literature on phage therapy, regulatory processes for antibacterial agents, and alternative approval mechanisms.
• Analysis of the unique properties of phages (replication, specificity, pharmacodynamics/pharmacokinetics) in the context of current drug approval frameworks.
• Discussion of specific alternative pathways such as adaptive licensing and "Right to Try" legislation.

Main Results:

• Current regulatory processes, designed for conventional antibiotics, are not well-suited for the unique characteristics of phages.
• Phage-derived products like endolysins may fit existing approval pathways as biological therapeutic proteins.
• The approval of whole phages faces significant regulatory and economic viability challenges.

Conclusions:

• The unique biological properties of phages present significant challenges for conventional drug approval processes.
• While phage-derived products may be approvable, whole phage therapy requires adaptation of current regulatory frameworks.
• Alternative regulatory pathways are essential to overcome hurdles and enable the clinical use of phage-based antibacterial agents.